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a b s t r a c t
The current standard of care for locally advanced cervical cancer is whole pelvis and
para-aortic radiation when indicated, delivered concomitantly with chemotherapy and
brachytherapy. Para-aortic node involvement is a predictor of survival in locally advanced
disease but presence of metastases is difficult to determine because the currently avail-
able imaging methods lack enough sensitivity to be able to detect accurately para-aortic
metastases when surgical staging is not feasible. The objective of this review is to describe
the current status of para-aortic lymph node irradiation in locally advanced cervical can-
cer. It includes analysis of the diagnostic imaging and surgical approaches for assessment
of para-aortic lymph node dissemination, together with indications for radiotherapy and
radiotherapeutic techniques.
© 2018 Greater Poland Cancer Centre. Published by Elsevier Sp. z o.o. All rights reserved.
1. Background
External beam radiotherapy (EBRT) and/or brachytherapy are
the two radiation modalities for the treatment of cervical
cancer and, combined with chemotherapy, remain the main
treatment with curative intent in locally advanced disease.
The Fédération Internationale de Gynecologie Obstetrique
(FIGO)1 considers cervical cancer to be locally advanced when
a tumour is more than 4 cm in diameter (FIGO stage IB2);
when the tumour grows into tissues adjacent to the cervix
and uterus (FIGO stage IIB); is present in the lower third of the
∗ Corresponding author at: Departamento de Radioterapia, Hospital Médica Sur, Puente de Piedra 150, Colonia Toriello Guerra, Delegación
Tlalpan CP 14050, CDMX, Mexico.
E-mail address: adepoite@hotmail.com (A. Poitevin Chacón).
vagina (FIGO stage IIIA); extends to the pelvic walls or lymph
nodes (FIGO stage IIIB) or into the bladder, rectum or outside
the pelvis (FIGO stage IVA). Radical hysterectomy is technically
challenging once pelvic tissues are affected and therefore not
indicated in a locally advanced disease.
The lymphatic system drains in from the cervix towards the
pelvic, para-aortic and supraclavicular nodes.2,3 Para-aortic
lymph node involvement has been associated with locally
advanced disease and is a prognostic factor for survival.4
Locally advanced cervical cancers are highly aggressive, with
higher rates of metastasis and worse survival outcomes than
an organ-confined disease.4 However, para-aortic lymph node
https://doi.org/10.1016/j.rpor.2018.09.009
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involvement is often difficult to confirm because imaging is
inconclusive and surgical visual confirmation not feasible.5
The reported incidence of para-aortic lymph node metastases
ranges from 17% to 37% of cases.6
Numerous studies7–11 have shown that concomitant
platinum-based chemoradiotherapy significantly improves
both overall survival and progression-free survival, represents
a major advance in the treatment of locally advanced cervical
cancer and continues to be the preferred treatment option.
Extended-field radiation therapy (EFRT), to the level of
the renal vessels (or even more cephalad based on involved
nodal distribution),12 is used both prophylactically and ther-
apeutically – depending on the extent of regional pelvic and
para-aortic lymph node involvement. The value of combin-
ing chemotherapy with EFRT has only been demonstrated in
patients with positive para-aortic nodes, whereas prophylac-
tic irradiation of the para-aortic nodes has not been proven to
have any significant benefit in patients with locally advanced
disease, especially those treated with chemoradiotherapy.13,14
The objective of this review is to describe the current status
of para-aortic lymph node irradiation in locally advanced cer-
vical cancer. It includes analysis of the diagnostic imaging and
surgical approaches for assessment of para-aortic lymph node
dissemination, together with indications for radiotherapy and
radiotherapeutic techniques.
2. Diagnostic imaging modalities
The FIGO cancer staging system1 takes into consideration
the following parameters: tumour diameter, parametrial inva-
sion, vaginal extension, infiltration of the bladder and rectal
mucosa, hydroureter, hydronephrosis, and metastasis. The
size of the primary tumour, the extension to parametria or
vagina and inguinal lymph nodes can be assessed clinically
by physical examination but imaging studies are required
to detect metastasis or invasion of the ureter. Pelvic mag-
netic resonance imaging (MRI) is mandatory for assessment
of pelvic tumour extension and to guide management.15
The presence of positive para-aortic lymph nodes is a key
predictor of survival. However, none of the currently available
imaging modalities has proven sufficiently sensitive to detect
para-aortic metastases in patients with locally advanced can-
cer. The para-aortic lymph nodes must always be assessed in
locally advanced cervical cancer in patients presenting with
positive pelvic nodes, tumour >2 cm, or metastatic lesions
in the common iliac nodes. The imaging modalities for this
purpose include ultrasound (US), computed tomography (CT),
MRI and positron emission tomography-computed tomogra-
phy (PET-CT).16,17
3. Ultrasound
Ultrasound offers many advantages. It is inexpensive, widely
available, and does not cause discomfort to the patient. More-
over, ultrasound allows physicians to determine the size
and location of the tumour in the cervix, visualise the cer-
vical topography, and identify the presence of parametrial
involvement.16,18,19 However, ultrasound is not considered an
appropriate method for assessing the extent of cervical can-
cer by the American College of Radiology; on a rating scale
from 1 to 9 for evaluating the appropriateness of different
imaging techniques when assessing cervical cancer, the Amer-
ican College of Radiology assigned a score of 2 to transvaginal
ultrasound.20
4. Computed tomography
Computed tomography is routinely performed for staging pur-
poses and to evaluate lymph node features. A pelvic node
with an axis >8 mm is considered enlarged and potentially
metastatic. Para-aortic nodes are considered enlarged if the
short axis measures >10 mm, with a sensitivity and specificity
of 80% and 92%, respectively.16 In the study by Liu et al.,21 the
diagnostic performance of CT showed 90% specificity and sen-
sitivity was lower than 60%. Results by Vandeperre et al.22 from
the University Hospitals of Leuven show that 82.6% of involved
para-aortic nodes are left-sided, and only 3.9% of para-aortic
metastases are not associated with pelvic disease, a finding
consistent with previous results.
5. Magnetic resonance imaging
Magnetic resonance imaging uses strong magnets with
phased array coils to obtain high contrast resolution images of
tissues.17,23 In particular, the finer soft tissue detail rendered
by MRI allows better risk evaluation for the irreversible ureteral
stenosis, or vesico-vaginal, recto-vaginal or utero-enteral fis-
tulae that may develop following chemoradiation. Moreover,
the ability to detect lymph node morphological features,
such as rounded shape, inhomogeneous signal intensity, and
spiculated margins increases the sensitivity of MRI in recog-
nising metastases.23 Laifer-Narin et al.24 reported that MRI
demonstrated greater than 90% specificity with less than
60% sensitivity in the detection of lymph node metastasis.
The main imaging criterion used to identify abnormal lymph
nodes was a short-axis diameter greater than 1 cm. Addi-
tional imaging features suggesting nodal metastasis include
a rounded shape, irregular margins, clusters of multiple small
lymph nodes, signal intensity similar to the primary tumour,
and necrosis.
6. Positron emission tomography with CT
In locally advanced cervical cancer or in early-stage disease
with suspicious lymph nodes on conventional imaging, PET-
CT or chest/abdomen CT are recommended for assessment of
nodal and distant disease. PET-CT is superior to both CT and
MRI in detecting lymph node metastases. The National Cancer
Comprehensive Network (NCCN) Cervical Cancer guideline12
recommends PET-CT for assessment of lymph-node involve-
ment and distant metastases in locally advanced cervical
cancer before chemoradiation therapy. PET-CT is also use-
ful to optimise radiotherapy treatment planning. Despite the
better accuracy of PET-CT versus CT alone, up to 32% of
patients with confirmed nodal invasion will be classified as
negative on PET-CT.25 The overall sensitivity of PET-CT in
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detecting metastatic disease is 36%, the overall false-negative
rate of para-aortic node involvement is around 12%, mainly
attributable to small non-detectable nodes (i.e. when lymph
nodes measure <5 mm). When considering patients with pos-
itive pelvic node uptake, the rate of false-negative para-aortic
involvement is 22%. However, up to 12% of cases may present
para-aortic metastases, even when the PET-CT is negative
mainly due to a failure in detection of micrometastases.26
Guoy et al.27 showed 85% sensitivity for para-aortic node
metastasis with a specificity of 95%.
PET-CT results were verified surgically by laparoscopic
extraperitoneal para-aortic lymphadenectomy in a study by
Atri et al. where the authors found that PET-CT had a sensitiv-
ity of 91.2%.28 The use of PET-CT to guide treatment was shown
to contribute to improved overall survival together with other
factors such as age, FIGO stage, histopathology, performance
status, body mass index, and concomitant platinum-based
chemotherapy in univariate and multivariate analyses in a
study by Hansen et al.26
Although PET-CT is generally considered superior to CT and
MRI in detecting lymph-node metastases, it is still inferior to
surgical staging regardless of the stage of cervical cancer. In
stage III disease, para-aortic lymph node staging using PET-CT
is an alternative to surgery.29
Radiation therapy planning can be optimised with flu-
orodeoxyglucose (FDG) PET-CT imaging by extending the
radiation target volume to encompass the para-aortic area, or
by modifying the dose to the involved lymph nodes.30 Pomel
et al. recently compared survival outcomes of patients with
laparoscopic surgical para-aortic lymphadenectomy and PET-
CT. The retrospective analysis showed that overall survival
(OS) and disease-free survival (DFS) were improved in patients
staged with PET-CT compared to those staged by surgery in
both univariate and multivariate analysis.31
7. Surgical staging
Surgical staging can be beneficial for detection of occult para-
aortic metastases in patients with negative PET-CT. It may also
have an impact on the decision between prophylactic or ther-
apeutic radiation in patients with para-aortic lymph nodes
<5 mm.32
Dissection at least to the level of the inferior mesenteric
artery may be considered prior to chemoradiotherapy and/or
brachytherapy. Quality of surgery, both parametrectomy and
lymph node dissection, is, however, of key importance in the
management of large (>4 cm) tumours. Intraoperative assess-
ment of lymph node status (frozen section) is recommended
as the first step. If lymph node involvement is detected intra-
operatively, including macro- or micro-metastases, further
pelvic lymph node dissection and radical hysterectomy should
be avoided and patients offered definitive chemoradiotherapy
and/or brachytherapy.33
If intraoperative lymph node assessment is negative or is
not done, systematic pelvic lymph node dissection should be
performed and a type C2 radical hysterectomy recommended.
Para-aortic lymphadenectomy is defined by the removal of
nodes located in the common iliac nodes up to the left renal
vein. There is ongoing debate among surgeons as to whether
the removal of nodes should be limited to the inframesen-
teric artery, to the right gonadal vein, or to the left renal vein.
Given the very low rate of skipped metastases above the infe-
rior mesenteric artery, ilio-inframesenteric dissection should
be an acceptable pattern of para-aortic lymph node dissection
including the removal of all lateroaortic, preaortic, interaor-
tocaval, precaval, and laterocaval nodes as in cervical cancer,
nodal metastases spread via the lymphogenous route in an
orderly fashion.34
Vandeperre et al. found that up to 8% of patients with neg-
ative imaging tests were positive on surgical evaluation and
that overall survival was significantly reduced in patients with
metastatic para-aortic lymph nodes diagnosed with surgery or
imaging.22
8. External beam radiotherapy
Irradiation of the aortic lymph nodes, known as extended
fields, is typically indicated in two distinct clinical scenar-
ios. As prophylaxis when nodal disease is not detected, by
imaging studies or lymph node sampling, or as therapeutic
when in the presence of risk factors such as lymphovascu-
lar invasion or positive pelvic nodes.35 Regardless of whether
the treatment plan is prophylactic or therapeutic, tech-
niques for extension into the para-aortic fields include the
anteroposterior–posteroanterior (AP–PA) fields, or a box tech-
nique with 4 fields, or intensity modulated radiotherapy
(IMRT).
The concept of extended field para-aortic irradiation was
first defined in the 1980s based on the RTOG 7920 protocol.36
The classical limits were determined according to boney refer-
ence points, with the upper limit located in the space between
T11–T12 or T12–L1 and the lower limit at L4–L5 and 1.5–2 cm
to each side of the vertebral body. The para-aortic and pelvic
regions were irradiated together under that protocol.
Semi-extended field radiation therapy refers to the inclu-
sion of the macroscopic tumour, uterus, parametrium, upper
third of the vagina, pelvic nodes (external and common inter-
nal iliac), and excludes the upper third of the para-aortic
lymph nodes at the level of the renal vessels, with the corre-
sponding margin.37 Notably, the site at which the renal vessels
emerge ranges from T12 to L2.38
Recently published guidelines for contouring the para-
aortic region describe delineation of the clinical target volume
(CTV) for para-aortic lymph nodes.36,38,39 The inferior vena
cava and aorta should be contoured from the level of the left
renal vein to the bifurcation of the aorta. The CTV should
extend 10 mm circumferentially and 15 mm laterally from the
aorta and 8 mm anteromedially and 6 mm postero-laterally
from the inferior vena cava. The CTV should be cropped to
avoid the vertebral body, muscle and bowel and extended the
posterior border to the anterior vertebral body and exclude the
RPC region above the L1–L2 interspace. Exclusion of the upper
para-aortic region (T12 to L1–L2 interspace) should be consid-
ered in node negative patients or where normal tissue toxicity
is a concern. The space around the aorta and the medial por-
tion of the inferior vena cava with a margin of 7 mm should be
included as the aortocaval and left para-aortic spaces are the
areas of greatest risk for nodal disease at this level.
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Intensity modulated radiotherapy significantly reduces
the dose to the organs at risk (gastrointestinal, genitouri-
nary, and hematologic) compared to conformal radiotherapy,
thus allowing for better and safer management of nodal
disease.40,41
Renald-Oldrini et al.42 performed a dosimetric comparison
for the para-aortic and pelvic nodes between volumetric mod-
ulated arc therapy (VMAT), an advanced form of IMRT that
delivers a precisely sculpted 3D dose distribution with a 360◦
rotation of the gantry in a single- or multi-arc treatment, and
tomotherapy, a form of CT-guided IMRT where radiation is
delivered slice-by-slice. Tomotherapy delivered lower doses to
the kidneys, an important advantage for patients who receive
nephrotoxic drugs.
A retrospective analysis conducted at four institutions
in France with median follow-up of 15 months evaluated
extended-field helical irradiation in locally advanced cervical
cancer.43 The study found low rates of acute genitourinary
and gastrointestinal toxicity, short-term outcomes in terms
of pelvic and para-aortic control and survival were similar to
those achieved with conformal techniques.
In cases with enlarged para-aortic nodes or positive PET-
CT, the prescription dose to the para-aortic nodes ranges
from 45 to 50.4 Gy. If feasible, an additional 5–10 Gy sequential
boost to the lymph nodes is recommended. IMRT is prefer-
able in this scenario to spare normal tissues, since the use
of IMRT to treat the para-aortic nodes is associated with low
rates of gastrointestinal toxicities and no duodenal-specific
toxicity, even in patients receiving concurrent chemotherapy
and dose escalation to 65 Gy or more. Dose escalation to the
para-aortic nodes has only become possible in recent years
with the development of IMRT and provides excellent dis-
ease control, with one study reporting nodal disease control
rate of 85% at 2 years post-IMRT with a median dose of 63
Gy.44
Wakatsuki et al.45 observed an association between node
disease recurrence to radiation dose and to node size after irra-
diation. In a retrospective analysis 245 patients were treated
with external beam radiotherapy with or without a boost plus
high-dose rate brachytherapy. The authors found a signifi-
cant correlation between node size after delivery of 50 Gy and
the control rate of metastatic nodes (<10 mm: 96.7%, ≥10 mm:
75.7%; p < 0.001), with no nodal recurrence if nodes received
>58 Gy (p = 0.001).
More recently, the use of IMRT with simultaneous inte-
grated boost (SIB) combined with platinum-based chemother-
apy reported 77% complete clinical and imaging response with
acceptable toxicity.46 The use of SIB in the treatment of nodal
disease allows for a small but considerable dose reduction
(3.8–4.4%) to the organs at risk, which results in a compara-
ble biological dose despite the higher dose fractions delivered
by the boost. Furthermore, SIB-IMRT reduces overall treatment
time and simplifies the planning process.47
Cibula et al. state that three-dimensional (3D) conformal
radiotherapy alone or as definitive para-aortic chemora-
diotherapy (platinum based) and/or 2D radiography based
brachytherapy is recommended if IMRT and/or imaging guided
adaptive brachytherapy (IGABT) are not available. The overall
treatment time when using 3D conformal radiotherapy and/or
2D radiography based brachytherapy should be respected. A
sequential lymph node boost is applied as appropriate after
completion of 3D EBRT.15
9. Results and toxicity
The risk of any grade (G1–G4) late toxicity at 3 years is 58% with
the use of chemotherapy according to Yap et al.48 Grade 3 tox-
icity was described in 16% of cases for pelvic EBRT and chemo
and in 49% if EFRT was delivered. Hematologic G3 toxicity can
reach 76% when para-aortic lymph nodes are included in the
treatment fields. Indeed, an important limitation to the use of
EFRT is toxicity, especially when it is administered postopera-
tively or concomitant with chemotherapy.
The use of EFRT is controversial because the available evi-
dence comes mostly from retrospective studies performed in
heterogeneous populations using different diagnostic tech-
niques. For example, in some studies the diagnosis was made
by laparoscopy whereas others have used imaging methods,
such as CT, MRI, or PET-CT with different sensitivities and
specificities. For these reasons, it is difficult to objectively
assess EFRT. However, Sapienza et al.49 conducted a meta-
analysis to evaluate studies that prophylactically irradiated
the para-aortic nodes to eliminate microscopic disease and
thus reduce the risk of distant metastasis. The meta-analysis
focused on phase III studies carried out in patients who
received the same systemic treatment. A total of 1000 patients
were included; of these, 506 received pelvic radiotherapy
while 494 underwent EFRT. Most of the EFRT patients (87.5%)
received prophylactic radiotherapy; aortic imaging studies
were not performed in 12.5% of patients. The review reported
that para-aortic lymph node treatment failure was lower in
the EFRT group compared to the group that received pelvic
radiotherapy alone (HR 0.35, 95% CI 0.19–0.64; p < 0.01). The
incidence of distant metastases was also lower (HR 0.69, 95%
CI 0.50–0.96; p = 0.03). Both arms received the same treatment
to the pelvis without a significant difference in locoregional
failure (OR 1.06, 95% CI 0.80–1.42; p = 0.67) although there
was a trend towards lower mortality in the EFRT group (OR
0.68, 95% CI 0.45–1.01; p = 0.06). However, it is worth not-
ing that only two studies reported treatment-related deaths.
The authors concluded that prophylactic EFRT decreased sys-
temic failure, but that new studies were needed to examine
other chemotherapy regimens and more modern radiotherapy
techniques.
Chantalat et al.6 retrospectively evaluated 155 patients
with para-aortic involvement confirmed by pathological
examination. Patients received platinum-based chemoradio-
therapy at a dose of 45 Gy delivered in 5 weeks followed by
intracavitary brachytherapy. Imaging studies were performed
at 6 weeks post-treatment. Relapses were observed in 45%
of patients. Para-aortic, loco-regional and distant relapses
were detected in 25%, 51% and 54%, respectively. Nearly
one in ten patients (9.6%) presented an isolated recurrence
in the para-aortic region. At 4 years, overall survival was
32.7% and DFS 28.8%. The prognosis of patients with lesions
<5 mm was better than those with larger lesions, leading
the authors to conclude that clinical stage was the most
important prognostic factor.
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Asiri et al.50 evaluated 102 stage IIB-IVA patients with
negative imaging studies, but positive pathological reports,
who were treated with EFRT. Patients were randomised to
receive either extended field chemoradiotherapy (n = 52) or
pelvic chemoradiotherapy (n = 50), followed by brachyther-
apy. At a median follow-up of 60 months, 74 patients had
completed the treatment protocol. Outcomes in the two
groups (extended field versus pelvic radiotherapy) were,
respectively: negative para-aortic nodes: 97% vs. 82%; dis-
tant metastasis control: 86.9% vs. 74.7%; DFS: 80.3 vs.
69%; overall survival: 60.4% vs. 60.4%. Grade 3/4 acute tox-
icity included neutropenia (2.6% in the EFRT group vs.
2.7%), grade 3 diarrhoea (2.6% in the EFRT group), and
grade 3 cystitis (2.7% in the pelvic radiotherapy group).
Late toxicity in the whole sample included intestinal
obstruction (2.6%) and chemotherapy-related hypoacusis
(2.8%).
Yap et al.48 evaluated the benefit of elective para-aortic
lymph node irradiation in patients with no clinical or radio-
graphic evidence of para-aortic involvement. A total of 228
patients were included; of these, 73 received EFRT and
155 pelvic radiotherapy. Both groups received conventional
chemotherapy. Mean follow up was 4.6 years. The primary
outcome DFS at 3 years was 49% and 73% in the EFRT and
pelvic radiotherapy groups, respectively, with local relapse
rates of 31.9% and 17.7%, respectively. Both outcomes were
associated with tumour size. The 3 year distant relapse rate
was higher in patients receiving EFRT (30.6% vs. 13.5%). Over-
all grade 3/4 toxicity in the EFRT group at 3 years was 11%
(proctitis 3%, urinary urgency 4%, and 1% each for fistula,
colitis, and neuropathy). Overall G3-4 toxicity in the pelvic
RT group was 8%, including proctitis (4%) and cystitis (3%).
These results suggested that EFRT provides no additional
benefit.
A review conducted by Hwang et al.16 concluded that
prophylactic EFRT might be useful in stage IB to IVA
cervical cancer patients with small (<5 mm) PET-CT neg-
ative para-aortic metastases confirmed with laparoscopic
lymphadenectomy. According to the authors, the available
evidence suggested that administering EFRT decreased the
risk of para-aortic recurrence at 8 years from 9% to 4%.
Gouy et al.51 showed disease-free survival in patients with
locally advanced cervical cancer with low-volume (<5 mm)
para-aortic node disease treated with EFRT chemoradiother-
apy, and who were misdiagnosed on PET-CT, was similar to
patients without para-aortic node spread and managed with
pelvic chemoradiotherapy alone. Conversely, in patients with
para-aortic node metastasis exceeding 5 mm, additional treat-
ment modalities should be explored because the survival rate
in these patients is poor.
Jung et al.52 evaluated a group of 45 patients who received
46 Gy radiotherapy to the pelvic and para-aortic regions and
14 Gy-boost to gross nodes, and 30 Gy in six fractions of
intracavitary brachytherapy. Overall, 9% of patients developed
gastrointestinal toxicity and 2% urinary toxicity. Approxi-
mately 80% of patients developed G3 haematological toxicity,
but no bone marrow protection was performed in that
study.
Toxicity, therefore, varies from study to study and appears
to depend largely on technique and dose.
10. Discussion
Metastatic involvement of the para-aortic lymph nodes is a
marker of poor prognosis in patients with cervical cancer.
However, at present, para-aortic nodal status is not considered
in the FIGO staging system. Targeted radiotherapy to these
nodes is required together with chemotherapy to improve
disease control.16 In patients with locally advanced cervical
cancer at high risk of occult para-aortic metastases, pro-
phylactic irradiation of the para-aortic lymph nodes seems
to offer little benefit when administered concomitantly with
platinum-based chemotherapy. Rates of local and distant
relapse remain high in these patients. The value of para-
aortic radiotherapy is also minimal in patients with extensive
uncontrolled pelvic disease or distant metastases.49
11. Future perspectives
The development of new, more accurate radiotherapy tech-
niques, together with dose escalation and daily soft tissue
imaging have led to a decrease in the exposure of healthy
organs to radiation. It is clear that better systemic treatments
are needed for patients with cervical cancer. Fortunately, new
approaches that combine radiotherapy and chemotherapy
with modern molecular therapies are emerging.53 These tar-
geted molecular therapies can treat resistant cell signalling
pathways that are likely to cause distant relapses. Another
approach involves neoadjuvant chemotherapy followed by
radiotherapy in patients with bulky para-aortic nodes who
are unlikely to respond to extended field radiation. Anti-
angiogenics is another new approach that may provide some
benefit in these patients. Stereotactic techniques should be
explored to administer limited, focal radiation in associa-
tion with aggressive immunotherapy or chemotherapy; such
an approach could be valuable because it would allow for
a shorter course of radiation with fewer adverse effects by
protecting the bone marrow and allowing for more intensive
chemotherapy. Finally, therapeutic vaccines are being devel-
oped that may be useful in locally advanced cervical cancer
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